Radiosynthesis and Evaluation of [18F]FEHSP990 as Novel PET Tracer for Hsp90 PET Imaging

IF 0.9 4区 医学 Q4 BIOCHEMICAL RESEARCH METHODS
Romy Cools, Koen Vermeulen, Sofie Celen, Renan C. F. Leitao, Guy Bormans
{"title":"Radiosynthesis and Evaluation of [18F]FEHSP990 as Novel PET Tracer for Hsp90 PET Imaging","authors":"Romy Cools,&nbsp;Koen Vermeulen,&nbsp;Sofie Celen,&nbsp;Renan C. F. Leitao,&nbsp;Guy Bormans","doi":"10.1002/jlcr.4144","DOIUrl":null,"url":null,"abstract":"<p>Heat shock protein 90 (Hsp90) is a critical chaperone in the protein quality control system, essential for maintaining cellular proteostasis. Aberrant Hsp90 function has been implicated in cancer and neurodegenerative disorders, making it an attractive therapeutic target and a potential biomarker for disease characterisation and progression using PET imaging. In this study, we aimed to develop the first fluorine-18 labelled brain permeable PET imaging agent, [<sup>18</sup>F]FEHSP990, suitable for imaging Hsp90 in both brain and tumour tissue. The radiosynthesis of [<sup>18</sup>F]FEHSP990 was achieved with a radiochemical yield of 48 ± 29%, high radiochemical purity of &gt; 99% and a molar activity of 213 ± 101 GBq/μmol at the end of synthesis. Competition binding studies in healthy mouse brain homogenate samples indicated a <i>K</i><sub><i>i</i></sub> value of approximately 200 nM. In vitro tracer binding to rodent brain and glioblastoma tumour tissue slices was high and deemed Hsp90-specific, as demonstrated by autoradiography blocking studies, whereas binding to living glioblastoma U87 cells was notably low. Ex vivo biodistribution and in vivo PET imaging studies in healthy rodents demonstrated limited brain exposure of the tracer, potentially due to insufficient affinity for Hsp90 and/or restricted blood–brain barrier permeability. Further development of fluorine-18 labelled Hsp90 tracers is warranted.</p>","PeriodicalId":16288,"journal":{"name":"Journal of labelled compounds & radiopharmaceuticals","volume":"68 4","pages":""},"PeriodicalIF":0.9000,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jlcr.4144","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of labelled compounds & radiopharmaceuticals","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jlcr.4144","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

Heat shock protein 90 (Hsp90) is a critical chaperone in the protein quality control system, essential for maintaining cellular proteostasis. Aberrant Hsp90 function has been implicated in cancer and neurodegenerative disorders, making it an attractive therapeutic target and a potential biomarker for disease characterisation and progression using PET imaging. In this study, we aimed to develop the first fluorine-18 labelled brain permeable PET imaging agent, [18F]FEHSP990, suitable for imaging Hsp90 in both brain and tumour tissue. The radiosynthesis of [18F]FEHSP990 was achieved with a radiochemical yield of 48 ± 29%, high radiochemical purity of > 99% and a molar activity of 213 ± 101 GBq/μmol at the end of synthesis. Competition binding studies in healthy mouse brain homogenate samples indicated a Ki value of approximately 200 nM. In vitro tracer binding to rodent brain and glioblastoma tumour tissue slices was high and deemed Hsp90-specific, as demonstrated by autoradiography blocking studies, whereas binding to living glioblastoma U87 cells was notably low. Ex vivo biodistribution and in vivo PET imaging studies in healthy rodents demonstrated limited brain exposure of the tracer, potentially due to insufficient affinity for Hsp90 and/or restricted blood–brain barrier permeability. Further development of fluorine-18 labelled Hsp90 tracers is warranted.

Abstract Image

[18F]FEHSP990作为Hsp90 PET显像新型示踪剂的放射性合成与评价
热休克蛋白90 (Hsp90)是蛋白质质量控制系统中重要的伴侣蛋白,对维持细胞蛋白稳态至关重要。异常的Hsp90功能与癌症和神经退行性疾病有关,使其成为一个有吸引力的治疗靶点和使用PET成像进行疾病表征和进展的潜在生物标志物。在本研究中,我们旨在开发第一种氟-18标记的脑透性PET显像剂[18F]FEHSP990,适用于脑和肿瘤组织中的Hsp90显像。[18F]FEHSP990的放射合成率为48±29%,放射化学纯度为>; 99%,合成结束时摩尔活性为213±101 GBq/μmol。在健康小鼠脑匀浆样品中的竞争结合研究表明Ki值约为200 nM。放射自显影阻断研究表明,体外示踪剂与啮齿动物脑和胶质母细胞瘤肿瘤组织切片的结合程度很高,被认为是hsp90特异性,而与活的胶质母细胞瘤U87细胞的结合程度明显较低。健康啮齿动物的体外生物分布和体内PET成像研究表明,示踪剂的脑暴露有限,可能是由于对Hsp90亲和力不足和/或血脑屏障通透性受限。进一步开发氟-18标记的Hsp90示踪剂是必要的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.30
自引率
0.00%
发文量
57
审稿时长
1 months
期刊介绍: The Journal of Labelled Compounds and Radiopharmaceuticals publishes all aspects of research dealing with labeled compound preparation and applications of these compounds. This includes tracer methods used in medical, pharmacological, biological, biochemical and chemical research in vitro and in vivo. The Journal of Labelled Compounds and Radiopharmaceuticals devotes particular attention to biomedical research, diagnostic and therapeutic applications of radiopharmaceuticals, covering all stages of development from basic metabolic research and technological development to preclinical and clinical studies based on physically and chemically well characterized molecular structures, coordination compounds and nano-particles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信